The ageing population and an increase in both
the incidence and prevalence of cancer pose a healthcare challenge, some
of which is borne by the orthopaedic community in the form of osteoporotic
fractures and metastatic bone disease. In recent years there has
been an increasing understanding of the pathways involved in bone
metabolism relevant to osteoporosis and metastases in bone. Newer
therapies may aid the management of these problems. One group of
drugs, the antibody mediated anti-resorptive therapies (AMARTs)
use antibodies to block bone resorption pathways. This review seeks
to present a synopsis of the guidelines, pharmacology and potential pathophysiology
of AMARTs and other new anti-resorptive drugs. We evaluate the literature relating to AMARTs and new anti-resorptives
with special attention on those approved for use in clinical practice. Denosumab, a monoclonal antibody against Receptor Activator for
Nuclear Factor Kappa-B Ligand. It is the first AMART approved by
the National Institute for Health and Clinical Excellence and the
US Food and Drug Administration. Other novel anti-resorptives awaiting
approval for clinical use include Odanacatib. Denosumab is indicated for the treatment of osteoporosis and
prevention of the complications of bone metastases. Recent evidence
suggests, however, that denosumab may have an adverse event profile
similar to bisphosphonates, including atypical femoral fractures.
It is, therefore, essential that orthopaedic surgeons are conversant
with these medications and their safe usage. Take home message: Denosumab has important orthopaedic indications
and has been shown to significantly reduce patient morbidity in
osteoporosis and metastatic bone disease. Cite this article:
Little is known about the incidence of rotator
cuff pathology or its demographic associations in the general population.
We undertook a large epidemiological study of rotator cuff pathology
in the United Kingdom using The Health Improvement Network (THIN)
database. The incidence of rotator cuff pathology was 87 per 100
000 person-years. It was more common in women than in men (90 cases
per 100 000 person-years in women and 83 per 100 000 person-years
in men; p <
0.001). The highest incidence of 198 per 100 000
person-years was found in those aged between 55 and 59 years. The
regional distribution of incidence demonstrated an even spread across
13 UK health authorities except Wales, where the incidence was significantly
higher (122 per 100 000 person-years; p <
0.001). The lowest
socioeconomic group had the highest incidence (98 per 100 000 person-years).
The incidence has risen fourfold since 1987 and as of 2006 shows
no signs of plateauing. This study represents the largest general population study of
rotator cuff pathology reported to date. The results obtained provide
an enhanced appreciation of the epidemiology of rotator cuff pathology
and may help to direct future upper limb orthopaedic services. Cite this article:
